Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study

Author:

Riasi Fatemeh1,Ataei Azimi Sajjad1,Allahyari Abolghasem2,Moeini Nodeh Mohammad1,Shakeri Mohammad T.3,Kamandi Mostafa1ORCID

Affiliation:

1. Department of Internal Medicine, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran

2. Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran

3. Department of Biostatistics, School of Health Mashhad University of Medical Sciences Mashhad Iran

Abstract

AbstractBackground and AimsThe effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R‐CHOP treatment regimens with and without vincristine reduction in DLBCL patients.MethodsThis retrospective study was conducted on newly diagnosed DLBCL patients during 2018–2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R‐CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared.ResultsOverall, 269 patients with DLBCL were included in this study, 15.99% of whom (n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R‐CHOP regimen (p > 0.05). Besides, no difference was observed in the 1‐year overall survival (OS) and progression‐free survival (PFS) of the patients in the two groups treated with R‐CHOP regimen with and without vincristine reduction (p > 0.05). The complete remission rates of the patients treated with R‐CHOP regimen with and without vincristine (p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R‐CHOP treatment regimen had no relationship with the 1‐year OS and PFS of the DLBCL patients (hazard ratio [HR]OS = 1.59, 95% confidence interval [CI]: 3.67–0.690, HRPFS = 1.67, 95% CI: 0.798–3.82).ConclusionThe results of this study showed that the reduction of vincristine from the R‐CHOP regimen in the DLBCL patients was not likely to make a difference in the 1‐year OS and PFS of the patients. However, further studies are needed on the issue.

Funder

Mashhad University of Medical Sciences

Publisher

Wiley

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3